Back to articles

Liver-related drug labeling, warnings differ in United States and Europe


An analysis of labeling for the same medications available in Europe and the United States showed that compared with FDA-approved labeling, European labels had a higher frequency of contraindications to product use in patients with liver disease or recommendations for dose modifications in liver impairment.


Bjornsson ES et al. Discrepancies in liver disease labeling in the package inserts of commonly prescribed medications. Gastroenterology. 2015;148:269–73.